Carlo Erba pharmacy and laboratory established
Farmitalia established, acquires farming estate in Nerviano as veterinary outstation
First ever anthracycline (Adriamycin) approved by FDA
Farmitalia-Carlo Erba merge to form Farmitalia/Carlo Erba (FICE)
FICE acquired by Kabi- Pharmacia To form Pharmacia
Pharmacia merge with The Upjohn Company to become Pharmacia&Upjohn (PNU)
PNU acquire SUGEN, becoming leaders of the kinase field
Aromasin approved by FDA
PNU merge with Searle/Monsanto to become Pharmacia
Pharmacia Acquired by Pfzier
Nerviano site spun off by Pfzier, acquired by CFIC and renamed as “Nerviano Medical Sciences, srl”, (NMS)
Encorafenib enabling IP licensed to Novartis.
Kinase platform agreement with Pfizer renegotiated, and a Region of Lombardy research foundation, “Fondazione Regionale per la Ricerca Biomedica (FRRB) takes over financial control of NMS
Entrectinib, Phase I sponsored by NMS, enters FIH clinical testing, in 3 separate, rationally selected indications.
Encorafenib approved by FDA in 2 independent indications.
Major stake in NMS is acquired by a Shanghai-based Chinese Venture Group, Hefei SARI V-Capital Management Co.
Enrectinib approved by FDA in 2 independent indications
NMS M801; P707; P912 and P807, all targeting different BIC/FIC mechanisms, programs start independent, mutinational, FIH clinical trials